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ABSTRACT 
 
 
The interaction of several biogenic amines and Compound A (2-(4-
acetoxyphenyl)-2-chloro- N-methyl-ethylammonium chloride), an analogue of the 
active substance in a HPLC fraction isolated from the shrub, Salsola 
tuberculatiformis Botsch., with cytochrome P450c11 was investigated. 
Noradrenaline, octopamine and Compound A inhibited the type I DOC induced 
difference spectrum of P450c11 and elicited a type II difference spectrum when 
added alone. The Ks-values for noradrenaline, octopamine, and Compound A 
were 0.8 mM, 0.16 mM and 0.36 mM, respectively. Dopamine, adrenaline and 
synephrine did not interact with, or inhibit, P450c11. Further investigation of 
Compound A indicated that it is a mixed inhibitor of sheep P450c11 with a 
stronger competitive (Kic = 106-110 M) than uncompetitive (Kiu = 667-737 
M) element. 
 
 
INTRODUCTION 
 
     During an investigation of bioactive substances in the Namibian shrub, Salsola 
tuberculatiformis Botsch., high performance liquid chromatography (HPLC) 
analyses of an 11-hydroxylase (P450c11) inhibiting fraction yielded two 
potentially active fractions. Further analyses of these two fractions indicated the 
presence of an aziridine in the first, and dopamine in the second fraction [1]. The 
aziridine containing fraction, labeled S2, inhibited the binding of 
deoxycorticosterone to P450c11 [2]. The active substance(s) in this fraction were, 
however, extremely unstable and activity was lost during exposure to light, 
oxygen and high pH. The major breakdown product of S2 was synephrine, which 
did not inhibit P450c11. This suggested that S2 contained a P450c11 inhibiting 
aziridine, aziridine precursor or biogenic amine. The presence of dopamine in the 
second fraction was therefore interesting and although dopamine did not inhibit 
P450c11, the possibility that it was a breakdown product of a more active 
biogenic amine precursor in the plant could not be ruled out. Aziridines are found 
in nature as mitomycins and are highly reactive N-tricyclic compounds used in 
cancer treatment [3]. The reactivity of aziridines prompted the use of more stable 
precursors in clinical studies [4]. The presence of the breakdown product, 
synephrine, and data obtained from masspectrometry (MS) and nuclear magnetic 
resonance (NMR) studies prompted the syntheses of a more stable precursor, 2-
(4-acetoxyphenyl) 2-chloro-N-methyl- ethylammonium chloride (Compound A), 
to assist in the investigation of the unstable active substance in S2 [5]. The 
influence of Compound A and a number of structurally related biogenic amines on 
ovine P450c11 was investigated. Spectral binding constants were determined for 
octopamine, noradrenaline, and Compound A. The mechanism of interaction of 
Compound A with P450c11 was further investigated with the aid of substrate 
induced difference spectra.  
 
 
MATERIALS AND METHODS 
 
 
Substrate Induced Difference Spectra 
 
     Lyophilised mitochondrial powder from sheep adrenals was used as a source 
of cytochrome P450c11 and the spectral assays were performed as previously 
published [2,5]. Compound A was prepared in PBS, immediately added to the test 
system, and spectra were recorded within 5 minutes; the biogenic amines were 
prepared in water. Two types of spectral assays were done: (1) substrate induced 
difference spectra by octopamine, noradrenaline, and Compound A and (2) 
inhibition of DOC-induced difference spectra by the same compounds. To 
determine the type of inhibition by Compound A spectral data was analyzed by 
nonlinear regression to determine sKmapp and sVmaxapp. The uncompetitive 
element (sKiu) was calculated by plotting 1/sVmaxapp vs inhibitor concentration 
(I) and the competitive element (sKic) calculated using the following formula [6]: 
sKmapp = sKm (1+I/sKic) / 1+I/sKiu 
 
 
RESULTS AND DISCUSSION 
 
 Figure 1A shows the interaction of noradrenaline, octopamine, and Compound 
A with P450c111. All three compounds inhibited the binding of DOC and elicited 
a Type II difference spectrum when added to the preparation in the absence of 
DOC. The Ks (spectral association constant) for the two biogenic amines and 
Compound A were determined using the double reciprocal plots shown in Figure 
1B. The Ks-values for noradrenaline, octopamine, and Compound A were 0.8mM, 
0.16mM and 0.36 mM, respectively. Structurally related amines, dopamine, 
adrenaline and synephrine, showed no inhibition of, or interaction with ovine 
adrenal P450c11 (results not shown). The results obtained with the biogenic 
amines were useful in designing the model compound, Compound A, as it 
indicated the importance of a functional group at position 2, adjacent to the 
phenyl ring. The catechol arrangement on the ring is not obligatory for activity as 
the monohydroxy octopamine was more active than the catechol, noradrenaline. 
These results also implied that a demethylated nitrogen was important for 
P450c11 interaction. However, the studies with Compound A indicated that this 
was not always the case and that activity may be modulated depending on the 
nature of the functional group at position 2. 
 
  
 Investigation of the substrate concentration dependent spectral changes in the 
DOC-induced difference spectrum, indicated that Compound A is a mixed 
inhibitor of sheep P450c11 with a stronger competitive (Kic = 106-110 M) than 
uncompetitive (Kiu = 667-737 M) element (Figure 2).  
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FIGURE 1  
Interaction of noradrenaline, octopamine, and Compound A with ovine P450c11 
(A) Substrate induced difference spectra and (B) double reciprocal plots to 
determine Ks. 
 
FIGURE 2  
Spectral changes in the DOC-induced difference spectrum by varying amounts (2-
50 M) of substrate (DOC) was measured in the presence of different 
concentrations (0-250 M) of Compound A. Spectra were recorded 5 min. after 
adding Compound A prepared in PBS. 
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